Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound alpha-ketoacid chewing tablet and preparation method thereof

A chewable tablet, ketoacid technology, applied in the direction of anhydride/acid/halide active ingredients, pill delivery, urinary system diseases, etc., can solve the problems of poor drug compliance, low bioavailability, inconvenience in swallowing, etc., to achieve convenient taking , high bioavailability, the effect of diversified oral dosage forms

Inactive Publication Date: 2009-04-29
无锡曙辉药业有限公司
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The purpose of the present invention is to overcome the disadvantages of compound α-ketoacid ordinary tablets in the prior art, such as inconvenient swallowing, slow disintegration, slow absorption, poor drug compliance, and low bioavailability, and provide a drug with good drug compliance, no Compound α-keto acid chewable tablet with disintegration process, fast absorption, high bioavailability and good taste and preparation method thereof

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The compound α-ketoacid chewable tablet of this embodiment is composed of the following formula, and the weight unit in the formula is g, which can be made into 1000 chewable tablets:

[0045] Calcium alpha-ketophenylalanine 68g

[0046] Calcium alpha-racemic hydroxymethionine 59g

[0047] Calcium alpha-ketoleucine 101g

[0048] Calcium Alpha-Rac-Keto-Isoleucine 67g

[0049] Alpha Ketovaline Calcium 86g

[0050] Tryptophan 23g

[0051] Histidine 38g

[0052] Tyrosine 30g

[0053] Threonine 53g

[0054] Lysine Acetate 105g

[0055] Lactose 30g

[0056] Starch slurry 10g

[0057] Aspartame Stevia Flavor Blend 110g

[0058] Magnesium Stearate Micronized Silica Gel 50g

[0059] Opadry 15g

[0060] The preparation method of the compound α-keto acid chewable tablet of this embodiment adopts the following process steps:

[0061] 1. Take the amino acid and amino acid calcium salt of the prescribed amount, add the lactose, aspartame, and stevioside of the prescribed a...

Embodiment 2

[0067] The compound α-ketoacid chewable tablet of this embodiment is composed of the following formula, and the weight unit in the formula is g, which can be made into 1000 chewable tablets:

[0068] Calcium alpha-ketophenylalanine 68g

[0069] Calcium alpha-racemic hydroxymethionine 59g

[0070] Calcium alpha-ketoleucine 101g

[0071] Calcium Alpha-Rac-Keto-Isoleucine 67g

[0072] Alpha Ketovaline Calcium 86g

[0073] Tryptophan 23g

[0074] Histidine 38g

[0075] Tyrosine 30g

[0076] Threonine 53g

[0077] Lysine Acetate 105g

[0078] Beta Cyclodextrin 40g

[0079] Povidone 12g

[0080] Cyclamate Sorbitol Flavor Blend 145g

[0081] Magnesium Stearate Polyethylene Glycol 30g

[0082] Opadry 12g

[0083] The preparation method of the compound α-keto acid chewable tablet of this embodiment adopts the following process steps:

[0084] 1. Weigh the prescribed amount of amino acid and amino acid calcium salt, add the prescribed amount of beta-cyclodextrin and sorbito...

Embodiment 3

[0090] The compound α-ketoacid chewable tablet of this embodiment is composed of the following formula, and the weight unit in the formula is g, which can be made into 1000 chewable tablets:

[0091] Calcium alpha-ketophenylalanine 68g

[0092] Calcium alpha-racemic hydroxymethionine 59g

[0093] Calcium alpha-ketoleucine 101g

[0094] Calcium Alpha-Rac-Keto-Isoleucine 67g

[0095] Alpha Ketovaline Calcium 86g

[0096] Tryptophan 23g

[0097] Histidine 38g

[0098] Tyrosine 30g

[0099] Threonine 53g

[0100] Lysine Acetate 105g

[0101] Microcrystalline Cellulose 50g

[0102] Povidone 15g

[0103] Cyclamate Xylitol Menthol Flavor Blend 160g

[0104] Magnesium Stearate Polyethylene Glycol 50g

[0105] Opadry 20g

[0106] The preparation method of the compound α-keto acid chewable tablet of this embodiment adopts the following process steps:

[0107] 1. Weigh the prescribed amount of amino acid and amino acid calcium salt, add the prescribed amount of microcrystall...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug preparation and a preparation method thereof, in particular to a compound Alpha-ketonic acid chewable tablet used for curing chronic renal failure, and a preparation method thereof. The compound Alpha-ketonic acid chewable tablet comprises the following components: Alpha-ketophenylalanine calcium, Alpha-hydroxymethionine calcium, Alpha-ketoleucine calcium, Alpha-ketoisoleucine calcium, Alpha-ketovaline calcium, tryptophan, histidine, tyrosine, threonine, lysine, acetate, a filling agent, a bonding agent, a taste-masking agent, a lubricant and a coating agent. The compound Alpha-ketonic acid chewable tablet not only widens the dosage form range of the compound Alpha-ketonic acid chewable tablets, but also has the advantages of having good dispersing state, short disintegration time, fast drug dissolution, rapid absorption, high biological availability and convenient taking, being capable of being swallowed, chewed and sucked and being especially suitable for old people, stroke patients, patients with special diseases and patients having swallowing difficulty.

Description

technical field [0001] The invention relates to a pharmaceutical preparation and a preparation method, in particular to a compound alpha-ketoacid chewable tablet and a preparation method for treating chronic renal failure. Background technique [0002] Since the development of hemodialysis and CAPD treatment in the 1960s and 1970s, nephrologists began to lose interest in the conservative treatment of renal failure. However, in the early 1980s, nutritional therapy for chronic renal failure aroused widespread attention again. In 1981, Franz VOLHARD observed that limiting daily protein intake could significantly improve the symptoms of uremia. It has been established that the severity of uremia symptoms is related to the accumulation of protein metabolic degradation products. Therefore, for many years, a low-protein diet has been used as a measure to relieve the symptoms of uremia. Moreover, a low-protein diet can reduce acid load and phosphorus intake, thereby preventing aci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/19A61P13/12
Inventor 陆继好
Owner 无锡曙辉药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com